The company’s 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2024, as both cannot be reliably forecasted. Any potential IPR&D and milestones expense related to the recently announced acquisition of Aliada Therapeutics is also excluded from AbbVie’s (ABBV) 2024 adjusted diluted EPS guidance, as the transaction is expected to close in the fourth quarter of 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie small cell lung cancer treatment granted FDA orphan designation
- Notable companies reporting before tomorrow’s open
- M&A News: AbbVie (NYSE:ABBV) Will Acquire Aliada Therapeutics for $1.4B
- AbbVie to acquire Aliada Therapeutics for $1.4B in cash
- Options Volatility and Implied Earnings Moves This Week, October 28 – November 01, 2024